Differential representation of liver proteins in obese human subjects suggests novel biomarkers and promising targets for drug development in obesity

Simonetta Caira, Antonio Iannello, Rosaria Sciarrillo, Gianluca Picariello, Giovanni Renzone, Andrea Scaloni and Pietro Adddeo

ABSTRACT
The proteome of liver biopsies from human obese (O) subjects has been compared to those of nonobese (NO) subjects using two-dimensional gel electrophoresis (2-DE). Differentially represented proteins were identified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)-based peptide mass fingerprinting (PMF) and nanoflow-liquid chromatography coupled to electrospray-tandem mass spectrometry (nLC-ESI-MS/MS). Overall, 61 gene products common to all of the liver biopsies were identified within 65 spots, among which 25 ones were differently represented between O and NO subjects. In particular, over-representation of short-chain acyl-CoA dehydrogenase, A3(3,5)-A2(4) dienoyl-CoA isomerase, acetyl-CoA acetyltransferase, glyoxylate reductase/hydroxypyruvate reductase, fructose-biphosphatase aldolase B, peroxiredoxin 1, protein DJ-1, catalase, α- and β-hemoglobin subunits, 3-mercaptopypyruvate S-transferase, calreticulin, aminocyclase 1, phenazine biosynthesis-like domain-containing protein and a form of fatty acid-binding protein, together with downrepresentation of glutamate dehydrogenase, glutathione S-transferase A1, S-adenosylmethionine synthase 1A and a form of apolipoprotein A-I, was associated with the obesity condition. Some of these metabolic enzymes and antioxidant proteins have already been identified as putative diagnostic markers of liver dysfunction in animal models of steatosis or obesity, suggesting additional investigations on their role in these syndromes. Their differential representation in human liver was suggestive of their consideration as obesity human biomarkers and for the development of novel antiobesity drugs.

Introduction
Obesity is often prodromal to severe degenerative liver diseases that can also progress to cirrhosis and hepatocellular carcinoma. It has been suggested that obese individuals undergo a progressive oxidative stress, due to increased levels of reactive oxygen and nitrogen species (ROS and RNS). The intricate mechanisms contributing to oxidative stress have been recently reviewed. The net result is that the oxidative stress leads to fat accumulation in non-adipose tissues, with subsequent development of obesity-associated comorbidities. Evidences for a general ROS involvement have been provided without the identification of the initiating events at cellular level. Finally, inflammatory processes modify the plasma levels of alanine transaminase, aspartate transaminase (AST), alkaline phosphatase, γ-glutamyl transferase and bilirubin, which are common plasma markers of the liver obesity status. However, these biomarkers are secreted also by other organs in response to pathological events and, hence, are nonspecific predictors of the liver damage. Thus, novel biomarkers are necessary to improve the accuracy of the diagnosis and to predict the ongoing dysfunction. The discovery of protein signatures may also disclose early-stage disease, supporting the screening of high-risk subjects and grounding the most appropriate treatment.

Clinical proteomics is deeply improving the relationships between proteomes, syndromes and diseases. In this context, quantitative proteomics recently allowed defining tentative protein patterns in the liver associated with specific diseases, including hepatocarcinoma (HCC)3-6. Regarding nonalcoholic steatosis (NAS), nonalcoholic fatty liver disease (NAFLD) and obesity, most of the proteomic studies performed so far were realized on hepatic extracts from animal models of the diseases, including ob/ob mice and hyperobese hypertensive rats subjected to a high-fat diet (HFD) or treated with drugs inducing steatosis7-20. In contrast, only few preliminary proteomic investigations have been performed on human patients, due to the difficulties in having corresponding liver specimens21-23. The present study was aimed at obtaining further insights into the liver protein changes associated with obesity by performing a proteomic comparison of biopsies from O and NO subjects, which was realized with integrated 2-DE, MS and bioinformatics techniques.

Methods
Sample of liver biopsies
Wedge liver biopsies were taken at the time of bariatric surgery (laparoscopic Roux-en-Y gastric bypass) or colorectal surgery for
the lean control, at the beginning of the procedure. Three out of 10 patients underwent surgery for colorectal disease including diverticular disease (n = 2) and colorectal adenoma (n = 1). The latter had no previous chemotherapy neither liver metastases.

Clinical information and liver samples from subjects with and without obesity were obtained after the approval by the Ethical Committee on Human Research of the participating hospitals and with patient consent. Table 1 reports the baseline clinical characteristics of subjects enrolled in the study. Specimens were taken at the level of the segment III of the liver and were quickly added to anhydrous ethanol, freeze-dried and stored at −80°C until analysis. A total of 10 biopsies were analyzed in this study. Seven biopsies were from independent patients with obesity with a body mass index (BMI) > 40 and three from independent subjects without obesity (BMI < 25) considered as potential candidates for living organ donation. Liver specimens of the subjects without obesity were histologically normal (absence of evident inflammation, fibrosis and pathological pattern).

Chemicals and solvents (HPLC-grade or better) were from Sigma-Aldrich (Milan, Italy).

Protein extraction
Liver biopsies were suspended in liquid nitrogen and ground to a fine powder in ∼10 vol of 700 mM sucrose, 500 mM Tris-HCl, pH 8.0, 50 mM EDTA, 100 mM KCl, 2% w/v β-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride and then vortexed for 15 min at 4°C. After addition of an equal volume of 500 mM Tris-HCl pH 7.5, the mixtures were vortexed for additional 10 min, centrifuged at 10,000×g for 15 min at 4°C and kept overnight at −20°C in cold saturated ammonium acetate and methanol. Insoluble proteins were pelleted at 10,000×g for 30 min, washed twice with cold methanol and then with cold acetone. Resulting dried pellets were re-suspended in 9 M urea, 4% w/v CHAPS, 0.5% v/v Triton X-100, 20 mM DTT and 1% w/v amphylole pH 3–10 (BioRad, Hercules, CA), extensively vortexed and finally centrifuged at 10,000×g for 10 min, at 20°C. Protein content was determined from the resulting supernatant using the RC/DC protein assay (Bio-Rad, Hemel Hempstead, UK). Aliquots (100 or 400 μg) of hepatic protein extracts were separated by analytical or preparative 2-DE gels, respectively.

Two-dimensional electrophoresis (2-DE)
First dimension isoelectric focusing (IEF) was performed on a Protean IEF Cell (Bio-Rad, Hercules, CA) using 18-cm ready IPG strips with a 3–10 linear pH gradient (Bio-Rad). Protein extracts were loaded onto the strips and soaked in the rehydration solution (final volume 315 μL) containing 8 M urea, 2% w/v 3-(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 0.3% w/v dithiotreitol, 2% IPG buffer pH 3–10 and 0.002% w/v Bromophenol Blue for 16 h, at 22°C. IEF was performed by applying a voltage of 250 V for 1 h, ramping to 1000 V over 5 h and holding at 8000 V until a total of 52 kVh was reached. Then, gel strips were equilibrated in 6 M urea, 30% w/v glycerol, 2% w/v SDS, 50 mM Tris-HCl pH 8.8, 0.01% w/v bromophenol blue and 2% w/v DTT for 20 min. Second dimension SDS-PAGE was carried out in 12% polyacrylamide gels (18 cm × 24 cm × 1 mm) in 25 mM Tris-HCl pH 8.3, 1.92 M glycine and 1% w/v SDS, using a Protean apparatus (Bio-Rad, Hercules, CA), with 70 V (135 mA) applied for 16 h. Three technical replicate analyses (including sample extraction and 2-DE separation) were carried out for each biological replicate. Gels were stained with Coomassie Brilliant Blue G-250.

Image acquisition and analysis
Stained gels were scanned at 95.3 μm/pixel resolution using a GS-800 Calibrated Imaging Densitometer (Bio-Rad, Hercules, CA). Resulting 12-bit images were analyzed using the PDQuest software (Bio-Rad, Hercules, CA, v.7.1). Spot detection and matching between gels were performed automatically, followed by manual validation. Only protein spots detected in all the gels were considered for the master gel construction. For quantitative analysis, the spot densities were normalized against the whole-gel densities, and the percentage volume of each spot was averaged for six different gels (3 replicates of 2 biological samples from each individual). Individual spot quantities were thus expressed as parts per million of the total integrated absorbance, after normalization against total image density. Statistical analysis (by Student’s t-test) was performed to find out significant protein representation differences between O and NO samples (control). A minimum 2-fold change in normalized spot densities was considered indicative for a differentially represented component. Each pattern was compared to the reference gel of the NO subjects. Constant spots occurring in all gel patterns were used as landmarks to facilitate image matching. Raw quantitative data for each spot were statistically analyzed and intergroup fold differences were calculated. The dynamic range of the protein expression was roughly estimated for 25 spots of each sample using the Image J analysis software (Bio-Rad, Hercules, CA). Quantitative data were obtained by normalizing the volume of each spot with respect to the corresponding one in the control. Statistical comparison of the densitometric data was carried out using the Student’s test for samples, and results were expressed as means ± standard deviation using SPSS 16.0 (SPSS Inc., Chicago, IL). Statistical significance was set at p < .05.

Spot digestion with trypsin
Gel spots were manually excised, reduced, alkylated with iodoacetamide and digested with proteomic-grade trypsin (Promega, Madison, WI).24 Protein digests were desalted/concentrated with ZipTip C18 devices (Millipore) prior to MALDI-TOF MS and/or nLC-ESI-MS/MS analysis.

Mass spectrometry
MALDI-TOF-PMF experiments were carried out on a Voyager DE-Pro instrument (PerSeptive Biosystems, Framingham, MA), using α-cyano-4-hydroxycinnamic acid (10 mg/mL in 50%, acetonitrile/0.1% trifluoroacetic acid) as the matrix. For PMF-based identification, spectra were acquired in the positive reflector ion mode. External mass calibration was performed with a dedicated kit of standard peptides (Sigma). Data were elaborated using the DataExplorer 5.1 software (Applied Biosystems, Foster City, CA).

### Table 1. Baseline clinical characteristics of the subjects enrolled in this study.

| Age (median, range) | Sex (F/M) | BMI (median, range) | Hypertension | Diabetes | Sleep apnea | Dyslipidemia | Arthrosis | Bariatric surgery | Colorectal surgery |
|---------------------|-----------|---------------------|--------------|----------|-------------|--------------|-----------|------------------|------------------|
| 42 (30–55)          | 4/3       | 42 (40–49)          | 3            | 1        | 1           | 1            | 1         | 7                | 0                |
| Lean group (n = 3)  | 49 (35–51)| 22 (21–25)          | 1            | 0        | 0           | 0            | 0         | 0                | 3                |

**Note:** The table represents the baseline clinical characteristics of the subjects enrolled in the study.
nLC-ESI-MS/MS analyzes were carried out using an Easy-nanoLC (Proxeon, Odense, Denmark) coupled to a LTQ XL mass spectrometer (Thermo Finnigan, San Jose, CA) equipped with a Proxeon nanospray source. Peptide mixtures were separated on a Proxeon Easy C18 column (100 x 0.075 mm, 3 μm) using a gradient of 0.1% v/v formic acid in acetonitrile and 0.1% formic acid in water. Acetonitrile ramped from 5% to 35% over 15 min and from 35% to 95% over 2 min, at a flow rate of 300 nL/min. Acquisition was controlled by a data-dependent product ion scanning procedure over the three most abundant ions, enabling dynamic exclusion (repeat count 2 and exclusion duration 1 min). The mass isolation window and collision energy were m/z 3 and 35%, respectively.

Protein identification

MASCOT software package version 2.2.06 (Matrix Science, UK) was used to identify protein spots from an updated nonredundant sequence database (NCBI nr 01/2013). MALDI-TOF-PMF data were searched using a mass tolerance value of 40–80 ppm, trypsin as proteolytic enzyme, up to two allowed missed cleavages, Cys carboxymethylation as fixed modification, Met-oxidation and N-terminal Gln-conversion to pyroglutamate as variable modifications. nLC-ESI-MS/MS data were employed to interrogate NCBI database, using a mass tolerance value of 2 Da for precursor ion and 0.8 Da for MS/MS fragments and proteolytic enzyme, missed cleavage and fixed/modification information reported earlier. Searches were taxonomically restricted to human proteins. MALDI-TOF-PMF candidates with a cumulative MASCOT score >82 and/or nLC-ESI-MS/MS candidates with more than two assigned peptides with an individual MASCOT score >25, both corresponding to p < 0.05 for a significant identification, were further evaluated by the comparison with their calculated mass and pI values, using the experimental values obtained from 2-DE. Protein identification was validated by measuring corresponding false positive discovery rate values (lower than 1%).

Functional classification of the differentially expressed proteins

Differentially represented proteins were examined according to the Protein ANalysis THrough Evolutionary Relationship (PANTHER) application (http://www.pantherdb.org) to standardize the representation of gene product attributes across species and databases. Sequence information was used to classify a gene to an ontology group according to the Gene Ontology (GO) terms (http://www.geneontology.org). Differentially represented proteins were clustered to GO according to their subcellular localization, primary biological process and molecular function.

Results and discussion

Liver proteome comparison between obese and nonobese subjects

The human liver proteome is strikingly complex; more than 6800 gene products have been described so far, which still represent a portion of the predicted 11,000 expressed genes. Due to the technological approach we used in the present study, our analysis was limited to proteins having a high-medium representation level in the liver, which were quantitatively evaluated as candidate obesity biomarkers. Worth mentioning is the fact that the specimens were from O and NO organs that did not show any pathological feature when histologically inspected; the latter came from lean subjects considered as potential candidates for living liver donation.

Some differences were observed amongst the O (panel A) and NO (panel B) subjects in explorative 2-DE analytical comparisons (Figure 1). This finding was confirmed by preparative experiments performed by analyzing higher protein amounts, which better highlighted some differentially represented proteins between O and NO subjects. In particular, although O subjects showed proteomic patterns affected by a certain individual variability (see below), a common quantitative trend was observed for specific proteins with respect to control. Protein spot features across all the gels were imported into a composite master gel (Figure 2). In this figure, green-circled features (25 in number) correspond to spots that significantly changed their representation between O and NO groups, while red-circled ones did not show significant variations among O/NO specimens. In the whole, 21 spots occurred as over-represented in the O group, whereas four ones were downrepresented.

Identification of liver proteins

Proteins present in the green and red-circled spots were identified by MALDI-TOF-PMF and/or nLC-ESI-MS/MS analysis and were associated with 61 sequence entries (Table 2). Identification details are reported in Supplementary Table S1. Among the differentially
represented spots in the O group, 23 ones contained a unique protein species, whereas two (spots 6 and 9) showed two components that comigrated within the gel as result of their similar mass and \( pI \) values. The volume data corresponding to the 25 differentially represented spots provided a rough estimation of the dynamic range of protein expression among the different O individuals (Table 3). Coherent data (at least 5 over 7 individuals) were observed for about 76% of the variable spots.

Differentially represented proteins were clustered according to GO terms for the corresponding molecular function, biological process and cellular component (Figure 3). More than 50% of the entries corresponded to protein effectors involved in metabolic processes, among which 60% corresponded to fatty acid-/phospholipid-binding proteins. Notably, nearly 10% of the differentially represented proteins were inflammation-related factors.

**Differentially represented proteins in obese subjects**

Recent observations already pointed out that no a unique molecule may be used as a marker candidate for obesity in human plasma, but rather a subset of components. These findings found a counterpart in results from various proteomic studies realized on liver tissues of animal models of steatosis, NAFLD and obesity. In this context, although exhibiting a variety of functions in the liver, most of the proteins here identified as differentially represented in O subjects have already been characterized as coherently deregulated in the liver of ob/ob mice and corpulent rats subjected to a HFD or treated with steatosis-inducing drugs. For example, increased levels of mitochondrial short-chain acyl-CoA dehydrogenase (spot 8) and \( \Delta(3,5)-\Delta(2,4) \) dienoyl-CoA isomerase (spot 12) (Table 3) have already been ascertained in the above-mentioned rodent models. Augmented protein amounts were also verified in the case of acetyl-CoA acetyltransferase (spot 6), glyoxylate reductase/hydroxyypyruvate reductase (spot 9) and AST (spot 6) (Table 3). Thus, over-representation of enzymes involved in fatty acid \( \beta \)-oxidation, ketogenesis, pyruvate metabolism and gluconeogenesis was suggestive for a deregulated process of acetyl-CoA generation/consumption in human O subjects (Figure 4), where the accumulation of this metabolite, as result of the augmented oxidative degradation of fatty acids and a higher metabolic activity of liver mitochondria, is redirected toward other metabolic pathways. The over-representation of fructose-biphosphate aldolase B (spot 7), which assists production of trioses phosphate for glycogen replenishment, and the down-representation of glutamate dehydrogenase (spot 3), which links together acetyl-CoA, \( \alpha \)-ketoglutarate and TCA cycle, were also in line with this scenario. Coherent quantitative levels of these enzymes have already been observed in murine models and obese humans (Table 3). Recently, short-chain acyl-CoA dehydrogenase, AST, fructose-biphosphate aldolase B and glutamate dehydrogenase have been identified as components of a multiprotein complex, containing other mitochondrial and cytosolic proteins, which integrates the different pathways mentioned above and possibly acts as an
| Spot | Proteins | SWISS PROT entry | NCBI entry | Spot | Proteins | SWISS PROT entry | NCBI entry |
|------|----------|------------------|------------|------|----------|------------------|------------|
| 1    | Calreticulin | CALR_HUMAN | 4757900    | 43   | Isocitrate dehydrogenase | IDHC_HUMAN | 28178825    |
| 2    | Catalase | CATA_HUMAN | 4557014    | 44   | Glutamate dehydrogenase 1, cytoplasmic | HPPD_HUMAN | 4504477    |
| 3    | Glutamate dehydrogenase 1, mitochondrial | DHE3_HUMAN | 4885281    | 45   | Catalase | CATA_HUMAN | 4557014    |
| 4    | S-adenosylmethionine synthetase isomerase type-1 | METK1_HUMAN | 417297    | 46   | Catalase | CATA_HUMAN | 4557014    |
| 5    | Aminoacylase-1 | ACY1_HUMAN | 461466     | 47   | Aldehyde dehydrogenase | ALDH2_HUMAN | 25777732 |
| 6    | Aspartate aminotransferase, cytoplasmic | AATC_HUMAN | 5902703    | 48   | Aldehyde dehydrogenase | ALDH2_HUMAN | 25777732 |
| 7    | Fructose-bisphosphate aldolase B | ALDOB_HUMAN | 1705823    | 49   | Protein disulfide-isomerase A3 | PDIA3_HUMAN | 21361657 |
| 8    | Short-chain-specific acyl-CoA dehydrogenase, mitochondrial | ACADS_HUMAN | 4557233    | 50   | Keratin, type II cytoskeletal 8 | K2C8_HUMAN | 4504919 |
| 9    | Aldo-keto reductase family member 1 | AK1C4_HUMAN | 708523     | 51   | Protein disulfide-isomerase A3 | PDIA3_HUMAN | 21361657 |
| 10   | Glyoxylate reductase/hydroxypyruvate reductase | GRHPR_HUMAN | 47116943   | 52   | Formimidoyltransferase-cyclodeaminase | FTCD_HUMAN | 11140815 |
| 11   | Phenazine biosynthesis-like domain-containing protein | TMTM_HUMAN | 61835204   | 53   | Formimidoyltransferase-cyclodeaminase | FTCD_HUMAN | 11140815 |
| 12   | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial | THTM_HUMAN | 62177133   | 54   | Keratin, type II cytoskeletal 8 | K2C8_HUMAN | 4504919 |
| 13   | Fructose-bisphosphate aldolase B | ALDOB_HUMAN | 4557395    | 55   | Keratin, type I cytoskeletal 18 | CH60_HUMAN | 31542947 |
| 14   | Glutathione S-transferase A1 | GSTA1_HUMAN | 22091454   | 56   | 60 kDa heat shock protein, mitochondrial | CH60_HUMAN | 31542947 |
| 15   | Peroxiredoxin-1 | PRDX1_HUMAN | 548453     | 57   | Vimentin | VIME_HUMAN | 62414289 |
| 16   | Protein DJ-1 | PARK7_HUMAN | 31543380   | 58   | Tubulin alpha-1B chain | TBA1_HUMAN | 193787715 |
| 17   | Apolipoprotein A-I | APOA1_HUMAN | 4557321    | 59   | Tubulin beta chain | TBBS_HUMAN | 18088719 |
| 18   | Hemoglobin subunit beta | HBB_HUMAN | 4504349    | 60   | Protein disulfide-isomerase | PDI1_HUMAN | 2507460 |
| 19   | Hemoglobin subunit beta | HBB_HUMAN | 4504349    | 61   | Alpha-1-antitrypsin | A1AT_HUMAN | 1703025 |
| 20   | Hemoglobin subunit beta | HBB_HUMAN | 4504349    | 62   | Calreticulin | CALR_HUMAN | 4757900 |
| 21   | Fatty acid-binding protein, liver | PBPL_HUMAN | 4504349    | 63   | 78 kDa glucose-regulated protein | GRP78_HUMAN | 16507237 |
| 22   | Fatty acid-binding protein, liver | PBPL_HUMAN | 4504349    | 64   | Annexin A6 | ANXA6_HUMAN | 113962 |
| 23   | Pterin-4-alpha-carbolamine dehydratase | PBPL_HUMAN | 4504349    | 65   | Endoplasmin | ENPL_HUMAN | 4507677 |
| 24   | Fatty acid-binding protein, liver | PBPL_HUMAN | 4504349    | 66   | V-type proton ATPase catalytic subunit A | VATA_HUMAN | 22096378 |
| 25   | Fatty acid-binding protein, liver | PBPL_HUMAN | 4504349    | 67   | Heat shock cognate 71 kDa protein | HSP7C_HUMAN | 123648 |
| 26   | Acyl-CoA-binding protein | ACBP_HUMAN | 118276     | 68   | Serum albumin | ALB_HUMAN | 4502027 |
| 27   | Hemoglobin subunit beta | HBB_HUMAN | 4504349    | 69   | V-type protein ATPase catalytic subunit A | VATA_HUMAN | 22096378 |
| 28   | Cytochrome c oxidase subunit 6B | CX6B1_HUMAN | 117115     | 70   | GTP cyclohydrolase 1 feedback regulatory protein | GFRP_HUMAN | 2506906 |
| 29   | GTP cyclohydrolase 1 feedback regulatory protein | GFRP_HUMAN | 2506906    | 71   | Fatty acid-binding protein, liver | FABPL_HUMAN | 4557577 |
| 30   | Fatty acid-binding protein, liver | FABPL_HUMAN | 4557577    | 72   | 78 kDa glucose-regulated protein | GRP78_HUMAN | 16507237 |
| 31   | Superoxide dismutase [Cu-Zn] | SOCD_HUMAN | 4507149    | 73   | Annexin A6 | ANXA6_HUMAN | 113962 |
| 32   | Eukaryotic translation initiation factor SA-1 | IFS3A1_HUMAN | 54037409   | 74   | Heat shock cognate 71 kDa protein | HSP7C_HUMAN | 123648 |
| 33   | GGT activator protein | GMFB_HUMAN | 4657579    | 75   | Serum albumin | ALB_HUMAN | 4502027 |
| 34   | Superoxide dismutase [Cu-Zn] | SOD1_HUMAN | 4507149    | 76   | V-type protein ATPase catalytic subunit A | VATA_HUMAN | 22096378 |
| 35   | Fatty acid-binding protein, liver | FABPL_HUMAN | 4557577    | 77   | Heat shock cognate 71 kDa protein | HSP7C_HUMAN | 123648 |
| 36   | Fatty acid-binding protein, liver | FABPL_HUMAN | 4557577    | 78   | Serum albumin | ALB_HUMAN | 4502027 |

(continued)
interpaths master controller\textsuperscript{30}. Also the over-representation of carbo-
nic anhydrase 2 (spot 13) in O subjects (Table 3) should be easily rationalized according to the picture reported in Figure 4, since this enzyme contributes to provide a significant portion of the bicarbonate for pyruvate carboxylase-assisted conversion of pyru-
vate into oxaloacetate in adipose metabolism\textsuperscript{31}. Increased levels of this protein have been associated with the process of adipocyte differentiation/maturati-
on\textsuperscript{12,33}. In this context, this and other carbo-
nic anhydrases have been identified as targets for the treatment and prophylaxis of obesity\textsuperscript{34}.

Regarding fatty acids and cholesterol transporters, which have already been described as differentially represented in the liver of the above-mentioned rodent models to face the increased concentration of these metabolites and to facilitate the corresponding metabolism/excretion\textsuperscript{5,14,17,21}, no quantitative changes were observed for spots associated with apolipoprotein A-I (apoA-I) and fatty acid-binding protein (FABP-1) (spots 26, 27, 28 and 34). Unique exceptions were specific protein isoforms (spots 17 and 22) (Table 3), which have already been associated with an acidic apoA-I form bearing oxidized Met and Trp residues observed in a murine model of HCC\textsuperscript{35}, and with a basic carboxylated FABP-1 form containing HNE- or glutathione-modified amino acids detected in a murine model of alcoholic liver disease\textsuperscript{9,24}, respectively. These modified species were reported to have a reduced transporter activity\textsuperscript{36,37}. Their differential representation in the liver of O subjects either matches with previous biochemical reports on rodent models\textsuperscript{14,17,33,39} and humans\textsuperscript{30,40} and was suggestive of an increased ROS activity therein\textsuperscript{1,6,21,42}. Accordingly, they may be considered as tentative pathological hallmarks that might help to decipher the traits of the abnormal lipid metabolism in obesity.

The observation of a ROS increase in the liver of O sub-
jects\textsuperscript{1,6,37,42} found a parallel in the measured over-representation of proteins involved in the response to oxidative insult, namely peroxiredoxin (PRX) I (spot 15), protein DJ-1 (spot 16) and catalase (CAT) (spot 2) (Table 3). For the latter protein, augmented levels were detected only for the most acid isoform, which corresponds to its phosphorylated, activated form\textsuperscript{9,36}. These and other antioxid-
ant proteins have already been reported as over-represented in above-mentioned rodent models\textsuperscript{5,10,15,17,18,42}. Their upregulation was ascribed to an attempt of the organ to contrast the oxidative burst generated from overloaded, fatty liver mitochondria\textsuperscript{1,4,42}. PRXs are abundant peroxidases that, through their thio-
redoxin peroxidase activity, maintain low levels of endogenous H\textsubscript{2}O\textsubscript{2}\textsuperscript{\textsuperscript{44,45}}; DJ-1 is an oxidative stress sensor protecting cells against oxidative insult\textsuperscript{46,47}. CAT is a peroxisomal antioxidant enzyme deputed to the inactivation of H\textsubscript{2}O\textsubscript{2} with quantitative levels modu-
lated from cell redox state\textsuperscript{45}. Since it has been reported that the oxidative burst can be considered either as first or second hit triggering hepatosteatotis development\textsuperscript{1,6,42}, it would be interesting to evaluate the quantitative evolution of these antioxidant proteins in subjects with incipient obesity.

The over-representation of \(\alpha\) - and \(\beta\)-hemoglobin subunits (spots 18–21 and 23–24) in O subjects (Table 3) was also associated with an antioxidant function. These proteins have already been identified as upregulated in the hepatocytes of NAS and NAFLD subjects\textsuperscript{48}. Their over-representation was not associated with erythropoiesis, but as related to the increased oxidative stress affecting the liver of the patients\textsuperscript{1,6,42}. In particular, hemoglobin was demonstrated to reduce this redox insult as result of its anti-
oxidative peroxidase activity\textsuperscript{48,49}. Both hemoglobin chains have already been proposed as plasma biomarkers for staging the liver damage\textsuperscript{50}.

Glutathione S-transferase (GST)-A1 (spot 14) and GST-Mu1 (spot 39) were also characterized as down-represented or constant in O specimens, respectively (Table 3). Reduced levels of these enzymes have already been observed in above-mentioned rodent models\textsuperscript{5,14,51} and in patients suffering these systemic metabolic altera-
tions\textsuperscript{21,22,52}. GSTs are liver-detoxifying enzymes that catalyze the conjugation of toxic xenobiotics and lipid peroxidation products with glutathione (GSH)\textsuperscript{53}. Since augmented levels of lipid peroxi-
ders and reduced levels of GSH have already been associated with a HFD\textsuperscript{21,29,53,54}, a reduced GSTs activity would not effectively counter-
treated increased levels of lipid peroxides in obese subjects, thus determining a significant protein oxidative modification, mitochondrial dysfunction and tissue damage\textsuperscript{52,55}.

Other enzymes involved in the metabolism of S-containing derivatives here observed as differentially represented in O subjects were S-adenosylmethionine synthase 1A (MAT1A, down-
represented, spot 4) and 3-mercaptopyruruvate S-transferase (3-MST, over-represented, spot 10) (Table 3). Their quantitative levels well correlated with that observed in the rodent models of metabolic dysfunction mentioned above\textsuperscript{20,21,42,57}. In particular, MAT1A is an essential enzyme for liver metabolism that catalyzes formation of S-adenosylmethionine (adoMet), an intracellular methylating effector and essential precursor for GSH biosynthesis. This protein helps maintaining normal liver functions, since MAT1A chronic hepatic deficiency results in the spontaneous development of non-
alcoholic steatohepatitis, oxidative stress and HCC\textsuperscript{15,42}. Our findings further support the important role of this protein in obesity-associated liver syndromes. On the other hand, 3-MST mediates the production of H\textsubscript{2}S from L-Cys in liver mitochondria, generating a gas that maintain organelle electron flow and supports cellular energetics\textsuperscript{56,57}. Our results provide a further evidence for the direct relation between the enhanced H\textsubscript{2}S-producing capacity of obese livers and the over-representation of 3-MST, which in this context should act as an antioxidant/anti-inflammatory molecule\textsuperscript{56,57}.

\[\text{Table 2. Continued} \]

| Spot | Proteins | SWISS PROT entry | NCBI entry | Spot | Proteins | SWISS PROT entry | NCBI entry |
|------|----------|------------------|------------|------|----------|------------------|------------|
| 37   | Heat shock protein beta-1 | HSPB1_HUMAN | 4504517   | 38   | Phosphatidylethanolamine-binding protein 1 | PEPT1_HUMAN | 450621   |
| 39   | Glutathione S-transferase Mu 1 | GSTM1_HUMAN | 23065544  | 40   | Thiosulfate sulfurtransferase | THTR_HUMAN | 17402865 |
| 41   | Betaine-homocysteine | BHMT1_HUMAN | 157266337 |
| 42   | S-methyltransferase 1 | BHMT1_HUMAN | 157266337 |

The first 25 spots reports proteins identified as differentially represented in the O subjects.
Table 3. Proteins identified as over- and down-represented in the liver of O subjects, compared to control (NO subjects).

| Spot | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     | 10    | 11    | 12    | 13    | 14    | 15    | 16    | 17    | 18    | 19    | 20    | 21    | 22    | 23    | 24    | 25    |
|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
|      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Protein          | Calreticulin | Catalase | Glutamate dehydrogenase 1 | Sadenosylmethionine synthetase isoform type 1 | Aminopeptidase | Acetyl-CoA acetyltransferase, mitochondrial | Acetyl-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic | Acdet-CoA acetyltransferase, mitochondrial, cytoplasmic |

Sample

1. \( \geq 0 < 5 \)
2. \( > 0 < -5 \)
3. \( > 5 < 10 \)
4. \( > 10 < -15 \)
5. \( > 15 < -20 \)
6. \( > 20 \)

The protein value was calculated by subtracting the average volume value of the NO subjects (assumed as reference data) to that of each measured spot. The protein in liver biopsies was judged to be positive or negative according to the higher or lower value than 0 score in comparison to the reference samples. Volume measurements (expressed as percentage) were indicated with + or − signs, depending on the degree of protein expression.
Figure 3. Gene Ontology (GO) annotation of identified proteins. The graphs show the percentages of corresponding GO terms to the 25 differentially represented components. The identified proteins were clustered according to three different criteria: cellular component, biological process, and molecular function.

Figure 4. Enzymes involved in fatty acid β-oxidation, ketogenesis, pyruvate metabolism and gluconeogenesis and acetyl-CoA generation/consumption deregulated process in human subjects with obesity. Over-represented proteins and promoted biological processes were underlined; down-represented proteins and reduced biological processes were in italics.
Finally, a positive correlation of our quantitative results with data from human and/or murine models of liver (metabolic) diseases was also observed for calreticulin (spot 1)56,59, aminocollase 1 (spot 13)60 and phenazine biosynthesis-like domain-containing protein (spot 11)61 (Table 3). An over-representation of the endoplasmic reticulum stress-marker calreticulin has already been associated with the inflammation affecting patients having systemic metabolic alterations and HFD62. Aminocollase 1 is Zn-dependent enzyme that hydrolyzes Ac-amino acids (including the antioxidant Ac-Cys) into acetate and amino acids; its increased representation was observed in the liver of a mouse model suffering inflammatory conditions60 and in a condition of Ac-Cys depletion62. It was demonstrated that aminocollase forms a regulatory/functional network with transketolase63 and interacts directly with sphingosine kinase 164; both protein couples have been proposed to have a role in the onset of obesity.

Conclusions

In this study, various proteins have been identified as differentially represented in the liver of O subjects, compared to control. Despite the low number of biopsies analyzed as result of the difficulties in collecting it, the nature of deregulated proteins matched that of differentially represented components ascertained in animal models of associated metabolic syndromes2–20 or in preliminary investigations on human obese patients21–23. We considered this observation as an independent validation of our results and, based on the reduced availability of corresponding tissues, it prompted us to avoid performing confirmative western blotting assays. In this context, the limited number of deregulated enzymes here detected, compared to that generally ascertained in animal models2–20, may be the consequence of human to mouse differences, reflect a softer metabolic dysfunction of the human subjects and/or depend on technical limitations associated with the liver amounts or to the gel-based approach we used.

Most of the components here identified as deregulated were associated with protein families already ascertained as highly affected in obesity-associated syndromes in rodent models7–20, namely metabolic enzymes and proteins involved in the response to an oxidative stress, confirming their role also in the human syndrome. For the first class, protein identity suggested that quantitative changes occurred at mitochondrial and cytosolic levels, and affected various metabolic pathways (fatty acid β-oxidation, ketogenesis, pyruvate metabolism and gluconeogenesis) involved in acetyl-CoA generation/consumption. These findings support previous studies reporting that obesity in humans is associated with a marked metabolic dysfunction in the liver, which may be dependent on a cellular redox imbalance at mitochondrial level1–6,42. Various hypothesis have been proposed regarding the possibility that the oxidative insult may be prodromal or additional for organ dysfunction. The observed over-representation of various antioxidant enzymes was in line with this scenario and was confirmative of the oxidative stress hepatocytes from obese subjects experienced and the reduced GSH levels present therein21,29,53,54. The nature of some FBP-1 and APOA-I isoforms, as detected here, suggested that some proteins become the target of oxidative modifications in obese subjects. In this context, a number of studies have already reported increased glutathionylated and carbonylated protein levels in animal models of NAFLD and NAS6,42,45,55,65–68. Future redox proteomics investigations combined with functional analysis will clarify the dynamics of these modifications and their effect on the active proteome of the liver in obese patients.

Specific differentially represented proteins (FBP-1, APOA-I and hemoglobin chains) transport lipids/nutrients within organs, cells or cell compartments. Some were reported to influence lipid homeostasis and inflammation, playing a role in the onset of obesity40,69,70. Their quantitative changes in human liver as result of the obesity income (Table 3) well paralleled with that already reported in plasma40,48,50,70. Thus, our data further support their use as clinically relevant biomarkers for obesity-like metabolic dysfunctions. Future studies are needed to validate the other deregulated proteins here identified and to link their levels to additional plasma biomarkers.

In conclusion, this study identified some metabolic enzymes and antioxidant proteins that have already been identified as putative diagnostic markers of liver dysfunction in animal models of steatosis or obesity. Their differential representation in human liver was suggestive of their consideration as potential biomarkers also for humans. Their quantitative representation suggests novel studies aimed at investigating the effect of their possible inhibition on obesity dysfunction; in this context, their identification can be considered as prodrome to the development of novel antiobesity drugs. In this context, some synthetic molecules have already been proposed as selective inhibitors of some of these enzymes and thus as antiobesity drugs. In particular, topiramate and zonisamide have already been reported as CA II inhibitors based on their capability to bind Zn2+ in the enzyme active site71. Similarly, 2-amino-bicyclo(2.2.1)-heptane-2-carboxylic acid (BCH) is a nonmetabolized analog of leucine that acts as a strong allosteric activator of GDH72. It stimulates the reductive amination through GDH activation thus reducing both de novo lipogenesis and gluconeogenesis. BCH has also been demonstrated to reduce liver collagen and plasma levels of alanine transaminase and aspartate transaminase. Finally, avasimibe has been reported to inhibit acetyl-CoA acyltransferase, thus reducing plasma total cholesterol and VLDL concentrations with an unknown mechanism.

Acknowledgements

This work was performed without a specific funding support by public or private institutions.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

References

1. Savini I, Catani MV, Evangelista D, et al. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci 2013;14:10497–538.
2. Matos JM, Witzmann FA, Cummings OW, Schmidt CM. A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res 2009;155:237–43.
3. Codarin E, Renzone G, Poz A, et al. Differential proteomic analysis of subfractionated human hepatocellular carcinoma tissues. J Proteome Res 2009;8:2273–84.
4. Cesarett L, Vascotto C, D’Ambrosio C, et al. Oxidative phosphoryldo as an immediate and sensitive marker of oxidative stress in HepG2 cells and its application to the redox effects induced by ischem/reperfusion in human liver. Free Radic Res 2005;39:255–68.
5. Kimhofer T, Fye H, Taylor-Robinson S, et al. Proteomic and metabolic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer 2015;112:1141–56.

6. Scalonì A, Codarini E, Di Maio V, et al. Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of proteomics and redox proteomics investigations. Clin Appl 2009;3:242–62.

7. Takahashi Y, Saejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012;18:2300–8.

8. Meneses-Lorente G, Watt A, Salim K, et al. Identification of early proteomic markers for hepatic steatosis. Chem Res Toxicol 2006;19:986–98.

9. Zhang X, Yang J, Guo Y, et al. Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 2010;51:1190–9.

10. Doupete P, Navet R, Gerkens P, et al. Steatosis-induced proteomic changes in liver mitochondria evidenced by two-dimensional differential in-gel electrophoresis. J Proteome Res 2005;4:2024–31.

11. Meierhofer D, Weidner C, Sauer S. Integrative analysis of transcriptomics, proteomics, and metabolomics data of white adipose and liver tissue of high-fat diet and rosiglitazone-treated insulin-resistant mice identified pathway alterations and molecular hubs. J Proteome Res 2014;13:5592–602.

12. Guo Y, Darshi M, Ma Y, et al. Quantitative proteomic and functional analysis of liver mitochondria from high fat diet (HFD) diabetic mice. Mol Cell Proteomics 2013;12:3744–58.

13. Edvardsson U, von Löwenhielm HB, Panfilov O, et al. Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics 2003;3:468–78.

14. Santamaria E, Avila MA, Latasa MU, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003;100:3065–70.

15. Wang X, Choi JW, Oh TS, et al. Comparative hepatic proteome analysis between lean and obese rats fed a high-fat diet reveals the existence of gender differences. Proteomics 2012;12:284–99.

16. Hölper S, Nolte H, Bober E, et al. Dissection of metabolic pathways in the Db/Db mouse model by integrative proteome and acetylene analysis. Mol Biosyst 2015;11:908–22.

17. Sabidó E, Wu Y, Bautista L, et al. Targeted proteomics reveals strain-specific changes in the mouse insulin and central metabolic pathways after a sustained high-fat diet. Mol Syst Biol 2013;9:681.

18. Meneses-Lorente G, Guest PC, Lawrence J, et al. A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol 2004;17:605–12.

19. Chang J, Oikawa S, Ichihara G, et al. Altered gene and protein expression in liver of the obese spontaneously hypertensive/NDmcpr-cp rat. Nutr Metab 2012b:9:87.

20. Eccleston HB, Andringa KK, Betancourt AM, et al. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal 2011;15:447–59.

21. Valle A, Catalán V, Rodríguez A, et al. Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. Liver Int 2012;32:951–61.

22. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665–74.
42. Mantena SK, King AL, Andringa KK, et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol and obesity-induced fatty liver diseases. Free Radic Biol Med 2008;44:1259–72.
43. Rhee SG, Yang KS, Kang SW, et al. Controlled elimination of intracellular \( \text{H}_2\text{O}_2 \): regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid Redox Signal 2005;7:619–26.
44. Latimer HR, Veal EA. Peroxiredoxins in regulation of MAPK signalling pathways; sensors and barriers to signal transduction. Mol Cells 2016;39:40–5.
45. Tsuchiya H, Ebata Y, Sakabe T. High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism 2013;62:1178–86.
46. Maceyka M, Nava VE, Milstien S, Spiegel S. Aminoacylase 1 is involved in fatty liver improvement. Proteomics 2013;13:1755–64.
47. Curtis JM, Hahn WS, Stone MD, et al. Protein carbonylation and adipocyte mitochondrial function. J Biol Chem 2012;287:32960–6.
48. Piemonte F, Petrini S, Gaeta LM, et al. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2008;23:e457–64.
49. Shi J, Zhang Y, Gu W, et al. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults. PLoS One 2012;7:e48777.
50. Curtis JM, Grimsrud PA, Wight WS, et al. Downregulation of adipose glutathione S-transferase A4 leads to increased protein carbonylation, oxidative stress, and mitochondrial dysfunction. Diabetes 2010;59:1132–42.
51. Rashid S, Alexander S, Roberts R. Enhanced synthesis of hydrogen sulfide in liver and kidney from Zucker diabetic fatty rats (ZDF) compared to Zucker Lean (ZL) rats. Nitric Oxide 2013;31:554.
52. Boden G, Duan X, Homko C, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008;57:2438–44.
53. Kurzawski M, Dziedziejko V, Urasińska E, et al. Nuclear factor erythroid 2-like 2 (Nrf2) expression in end-stage liver disease. Environ Toxicol Pharmacol 2012;34:87–95.
54. Bachi A, Dalle-Donne I, Scaloni A. Redox proteomics: chemical principles, methodological approaches and biological/medical promises. Chem Rev 2013;113:596–698.
55. Knobbe CB, Revett TJ, Bai Y, et al. Choice of biological source material supersedes oxidative stress in its influence on DJ-1 in vivo interactions with Hsp90. J Proteome Res 2011;10:4388–404.
56. Rashid S, Alexander S, Roberts R. Enhanced synthesis of hydrogen sulfide in liver and kidney from Zucker diabetic fatty rats (ZDF) compared to Zucker Lean (ZL) rats. Nitric Oxide 2013;31:554.